Coenzyme Q10 and its role in heart disease

Journal of Clinical Biochemistry and Nutrition

Volumn 26, Issue 2, 1999, Pages 109-118

  Singh, Ram B ^a   Niaz, Mohammad A ^b   Rastogi, Shanti S ^b   Verma, Satya P ^b  

^a Medical Hospital and Research Centre Moradabad   (India)

^b Appolo Hospital   (India)

Author keywords

Cardiomyopathy; Coronary artery disease; Heart failure; Hypertension; Myocardial infarction; Ubiquinone

Indexed keywords

ANGINA;

EID: 0032694545     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.26.109     Document Type: Conference Paper

References (41)

1. 10. A new drug for cardio-vascular disease. J. Clin. Pharmacol., 30, 596-608.
2. Ernster, L., and Dallner, G. (1995): Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta, 1271, 195-204.
3. Singh, R.B., Niaz, M.A., Rastogi, V., and Rastogi, S.S. (1998): Coenzyme Q in cardiovascular disease. JAPI, 46, 299-306.
4. Kagan, V., and Packer, L. (1993): Electron transport regenerates vitamin E in mitochondria and microsomes via ubiquinone: An antioxidant duet, in Free Radicals and Antioxidants and Nutrition, ed. by Corongni, F., Banni, S., Desai, M.A., and Rice-Evans, C., Richelieu Press, London, pp. 27-36.
5. Stoeker, R., Bowry, W.V., and Frei, B. (1991): Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. U.S.A., 88, 1646-1650.
6. Merati, G., Pasquali, P., Vergani, C., and Landi, L. (1992): Antioxidant activity of ubiquinone-3 in human low density lipoprotein. Free Radical Res. Commun., 16, 11-17.
7. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta, 1126, 247-254.
8. Esconde, D., and Cavero, I. (1992): Potassium channel openers: Moving towards cardio-protection via strengthening of a natural mechanism. Trends Pharmacol. Sci., 13, 269-272.
9. Sundarroa, M., and Quinn, P. (1986): Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid membranes. Int. J. Biochem., 155, 353-358.
10. Niki, E. (1993): Chemistry and biochemistry of vitamin E and coenzyme Q as antioxidants, in Free Radicals and Antioxidants in Nutrition, ed. by Corongiu, F., Banni, S., Desai, N.M.A., and Rice-Evans, C., Richelieu Press, London, pp. 13-25.
11. Grech, E.D., Jackson, M., and Ramsdale, D.R. (1995): Reperfusion injury after acute myocardial infarction. Br. Med. J., 310, 477-478.
12. Singh, R.B., and Niaz, M.A. (1996): Antioxidants, oxidants and free radical stress in cardiovascular disease. J. Assoc. Physicians India, 44, 43-48.
13. 10 of patients with myocardial disease classes III and IV, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 4, ed. by Folkers, K., and Yamamura, Y., Elsevier, Amsterdam, pp. 325-339.
14. 10 on exercise tolerance in chronic stable angina pectoris. Am. J. Cardiol., 56, 247-251.
15. 10 on ischaemia-induced ST-segment depression: A double blind placebo controlled crossover study, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, ed. by Folkers, K., and Yamamura, Y., Elsevier, Amsterdam, pp. 385-394.
16. 10 in patients with chronic stable effort angina and moderate heart failure. Curr. Ther. Res., 41, 923-930.
17. 10 in ischaemic cardiopathy, in Biomedical and Clinical Aspects of Coenzyme Q, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 321-326.
18. 10 therapy and exercise duration in stable angina, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 339-348.
19. Bresolin, N., Moroni, I., Angilini, C., Doriguzzic, C., Castelli, E., Banfi, P., Liciardelic, L., Carenzi, A., Comi, G., and Scarlato, G. (1991): Ubiquinone treatment in patients with mitochondrial myopathies: The first double blind trial, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 397-405.
20. 10 treatment of heart failure in elderly: Preliminary results, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 473-480.
21. 10 as an adjunctive in treatment in congestive heart failure. J. Am. Coll. Cardiol., 19 (Suppl.), 774-776.
22. 10 therapy in patients with congestive heart failure: A long term multicentre randomized study. Clin. Invest., 71 (Suppl.), 134-136.
23. 10 (CoQ) to treat patients with cardiomyopathy and CoQ levels in blood and endomyocardial biopsies, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 4, ed. by Folkers, K., and Yamagami, T., Elsevier, Amsterdam, pp. 391-402.
24. 10 (Ubiquinone) bei der iangzeitbehandlung der dilatativen kardiomyopathie. Z. Kardiol., 78, 360-365.
25. 10 treated congestive heart failure patients compared to conventionally treated patients, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 291-298.
26. Dhalla, N.S., Hill, M.F., and Singal, P.K. (1996): Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol., 28, 506-514.
27. 10 administration. Mol. Aspects Med., 18, 299-305.
28. 10 illuminated by meta-analysis of clinical trials. Mol. Aspects Med., 18, 159-168.
29. 10 during heart surgery. Clin. Invest., 71 (Suppl.), 155-161.
30. 10 after coronary artery bypass grafting, in Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, ed. by Folkers, K., Littarru, G.P., and Yamagami, T., Elsevier, Amsterdam, pp. 357-359.
31. 10 in patients with acute myocardial infarction. Cardiovasc. Drugs Ther., 12, 347-353.
32. 10 in essential hypertension. Mol. Aspects Med., 15 (Suppl.), 275-283.
33. 10. Mol. Aspects Med., 15 (Suppl.), 265-272.
34. Iarussi, D., Auricchio, U., Murano, A., Giuliano, M., Di Tullio, M.T., and Iacono, A. (1994): Protective effect of coenzyme Q on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Mol. Aspects Med., 15 (Suppl.), 207-212.
35. 10 lowering effect by HMG-CoA reductase inhibitors: A double blind placebo controlled. J. Clin. Pharmacol., 33, 226-229.
36. 10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int. J. Clin. Lab. Res., 24, 171-176.
37. Singh, R.B., Singh, N.K., Rastogi, S.S., Wander, G.S., Aslam, M., Onouchi, Z., and Kummerow, R.A. (1997): Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc. Drugs Ther., 11, 575-580.
38. 10 in patients with acute coronary artery disease. Discovery of a new role. Int. J. Cardiol., 68, 23-29.
39. 10 on blood pressures, and insulin resistance in hypertensive patients with eoronary artery disease. J. Hum. Hyperten., 13, 203-208.
40. 10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J. Cardiovasc. Pharmacol., 29, 16-22.
41. 10 and antioxidants in acute myocardial infarction. Mol. Aspects Med., 15 (Suppl.), 143-147.